Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

With this in mind, what's the best play? Stay on the sidelines.

There Is No Good Play When It Comes to INO Stock

Inovio stock has spiked sharply on hopes of a vaccine for the COVID-19 virus. But the real story of the stock lies in its pipeline.

Inovio Stock Is Moving for the Wrong Reason

Gilead Sciences

Moderna

Novavax

The COVID-19 inspired rally in these four biotech stocks is hitting fever pitch in pre-market action Thursday morning.

Why Inovio Pharmaceuticals, Gilead Sciences, Moderna, and Novavax Are All Jumping Today

Vaxart

Healthcare companies are trying to find a cure and contain the coronavirus outbreak. This keeps the industry in focus

4 Healthcare Stocks to Gain as Coronavirus Threat Looms Large

The biotech is developing a potential vaccine for the coronavirus. Its pipeline is chock-full of other candidates.

Should You Buy Inovio Pharmaceuticals Stock Right Now?

Apple

iShares Russell 2000 ETF

Royal Caribbean Cruises

Starbucks

SPDR S&P Biotech ETF

My Initial Coronavirus Trading Plan

Inovio doesn't have much to show for the last 20 trading years. Don't let the coronavirus effect convince you to buy INO stock now.

Inovio Stock Is Still a Highly Speculative Trade

The COVID-19 respiratory disease is quickly morphing into a pandemic.

Why Inovio Pharmaceuticals and Novavax Are Exploding Higher Today

The pharmaceutical company received a lot of positive media attention over the weekend.

Here's Why Inovio Pharmaceuticals Popped Today

Johnson & Johnson

The COVID-19 virus is putting a wrinkle in the agency's activities.

The FDA Has a Plan to Deal With the Coronavirus

Investors may want to think twice before buying this vaccine stock on the heels of the COVID-19 threat.

Is Inovio Pharmaceuticals a Screaming Buy?

The biotech could start testing its coronavirus vaccine as early as this summer.

Here's Why Inovio Pharmaceuticals Stock Rocketed Higher Today

Investors sold off INO stock when they remembered that launching a coronavirus vaccine would take at least a few months.
The post Inovio’s Surge on a Coronavirus Vaccine Was Just Speculation appeared first on InvestorPlace.

Inovio’s Surge on a Coronavirus Vaccine Was Just Speculation

Inovio Pharmaceuticals (INO) closed the most recent trading day at $3.34, moving -1.47% from the previous trading session.

Inovio Pharmaceuticals (INO) Stock Sinks As Market Gains: What You Should Know

Like many pharmaceutical companies, Inovio loses a lot of money. As of September 30, 2019, it had an accumulated deficit of $702 million, which means it’s lost $702 million over its history.

What Inovio Pharma’s $100 Million Addition to Its Shelf Offering Means for INO Stock 

INO stock initially enjoyed tremendous momentum due to the underlying small-cap pharmaceutical delivering a coronavirus vaccine. However, this is a story that has been repeated many times in the past, each time leading to disappointment.

Pandemic Fears Not Enough to Buy Inovio Stock

The FDA accepts Inovio's (INO) IND application for INO-3107 to initiate a phase I/II study for the treatment of recurrent respiratory papillomatosis, a rare disease caused by HPV. Stock up.

Inovio Gets FDA Nod to Begin Study on INO-3107, Stock Gains

Several factors both cloud and bolster the narrative for INO stock. Ultimately though, the underlying company’s technology is worth a speculative gamble.

3 Pros and 3 Cons For INO Stock Amid Chinese Coronavirus Outbreak

The company is starting a new clinical trial, but that may not be the only thing boosting the biotech's shares.

Here's Why Inovio Pharmaceuticals Jumped Higher Today

The INO stock flash and crash should serve as a warning to traders trying to get rich off of every news development.

Inovio’s Pop and Drop Is a Lesson Against Chasing Headlines

BioCryst Pharmaceuticals

These five biotechs are likely to remain on the volatile side this week, thanks to the novel-coronavirus threat.

Could These 5 Stocks Benefit From the Coronavirus Outbreak?

Is  (INO) Outperforming Other Medical Stocks This Year?

Is Inovio Pharmaceuticals (INO) Stock Outpacing Its Medical Peers This Year?

Vir Biotechnology

Gilead Sciences may be winning the race to develop the first coronavirus treatment.

Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today

Regeneron Pharmaceuticals

Some biotech firms have been outperforming the market over the past few weeks on their treatment initiatives.

Investors rush into biotechs working on coronavirus vaccine

Aethlon Medical

NanoViricides

The story that has dominated this past week is that China is facing an outbreak of the coronavirus, and more countries around the world are seeing cases pop up.

News for Inovio Pharmaceuticals Stock (INO)